Intellia Therapeutics (NTLA) Accumulated Depreciation & Amortization (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $49.7 million as the latest value for Q4 2024.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 24.66% to $49.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $49.7 million, a 24.66% increase, with the full-year FY2024 number at $49.7 million, up 24.66% from a year prior.
- Accumulated Depreciation & Amortization was $49.7 million for Q4 2024 at Intellia Therapeutics, up from $39.9 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $49.7 million in Q4 2024 to a low of $19.3 million in Q4 2020.
- A 5-year average of $33.6 million and a median of $33.2 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 39.39% in 2020, then rose 20.07% in 2023.
- Intellia Therapeutics' Accumulated Depreciation & Amortization stood at $19.3 million in 2020, then surged by 35.09% to $26.1 million in 2021, then rose by 27.13% to $33.2 million in 2022, then rose by 20.07% to $39.9 million in 2023, then rose by 24.66% to $49.7 million in 2024.
- Per Business Quant, the three most recent readings for NTLA's Accumulated Depreciation & Amortization are $49.7 million (Q4 2024), $39.9 million (Q4 2023), and $33.2 million (Q4 2022).